Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301

PURPOSE: Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) compared lazertinib versus gefitinib in treatment-naïve patients with EGFR-mutated (exon 19 deletion [ex19del]/L858R) locally ad...

Full description

Saved in:

Bibliographic Details
Main Author:	Cho B.C.
Other Authors:	Mahidol University
Format:	Article
Published:	2023
Subjects:	Biochemistry, Genetics and Molecular Biology
Online Access:	https://repository.li.mahidol.ac.th/handle/123456789/90011
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Mahidol University

Similar Items

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
by: Reungwetwattana T.
Published: (2023)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
by: Wang D.D., et al.
Published: (2019)

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
by: Chaichana Chantharakhit
Published: (2019)

Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations
by: Haaland, B., et al.
Published: (2016)

Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
by: You, R., et al.
Published: (2021)

Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
by: Thanyanan Reungwetwattana, et al.
Published: (2022)

Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung
by: De Lima Lopes Jr., G., et al.
Published: (2016)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Lee C., et al.
Published: (2017)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
by: Chee Khoon Lee, et al.
Published: (2018)

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
by: Ku, G.Y., et al.
Published: (2016)

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
by: Mark Boye, et al.
Published: (2018)

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
by: James Chih Hsin Yang, et al.
Published: (2018)

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
by: Tan, P.-T, et al.
Published: (2020)

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer
by: Ali, A, et al.
Published: (2020)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
by: Park, Keunchil, et al.
Published: (2022)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Wu Y., et al.
Published: (2017)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)

CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer
by: Thanyanan Reungwetwattana, et al.
Published: (2019)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Fukuoka M., et al.
Published: (2017)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
by: Masahiro Fukuoka, et al.
Published: (2018)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
by: Wong, A.S., et al.
Published: (2014)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
by: Afrita Amalia Laitupa, -, et al.
Published: (2019)

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer
by: Sudo, M., et al.
Published: (2014)

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
by: Saifon W.
Published: (2023)

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)
by: Yuankai Shi, et al.
Published: (2018)

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)
by: Yuankai Shi, et al.
Published: (2018)

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)
by: Shi Y., et al.
Published: (2014)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014)

Impact of smoking and brain metastasis on outcomes of advanced EGFR mutation lung adenocarcinoma patients treated with first line epidermal growth factor receptor tyrosine kinase inhibitors
by: Jain A., et al.
Published: (2020)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
by: Byoung Chul Cho, et al.
Published: (2018)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014)

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert,S., et al.
Published: (2015)

Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective
by: Thongprasert S., et al.
Published: (2014)

The role of monoclonal antibody in combination with first-line chemotherapy in Asian patients with advanced non-small cell lung cancer
by: Cho, B.C., et al.
Published: (2014)

Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
by: J. Chantharasamee, et al.
Published: (2020)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
by: Costa D.B., et al.
Published: (2018)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)